EpiEndo Pharmaceuticals has appointed two new non-executive board members following the departure of Robert Helgason, who stepped down at the Company’s AGM on 26 April 2022.
EpiEndo Pharmaceuticals is an Icelandic clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract and skin.
EpiEndo Pharmaceuticals is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract tract and skin.
EpiEndo is a clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, GI tract and skin.
EpiEndo Pharmaceuticals is pleased to announce that it is the recipient of this year’s Rising Star Award at the Swedish American Life Science Summit (SALSS).